Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment [0.03%]
GLP-1受体激动剂和SGLT2抑制剂对肾功能不全2型糖尿病患者的影响分析
Takeyuki Hiramatsu,Hiroki Ito,Shota Okumura et al.
Takeyuki Hiramatsu et al.
Introduction: Diabetes mellitus is a progressive disease with cardiovascular complications. We evaluated the impact of a glucagon like peptide-1 (GLP-1) receptor agonist and sodium glucose cotransporter 2 (SGLT-2) inhibit...
R C Sagar,F Phoenix,G Thanabalasingham et al.
R C Sagar et al.
Background: Fibrin network characteristics determine predisposition to cardiovascular disease (CVD). Individuals with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) have higher risk of CVD and display deranged fibrin n...
Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME® [0.03%]
EMPA-REG OUTCOME®试验中心血管结局和LDL胆固醇水平的关系
Gisle Langslet,Bernard Zinman,Christoph Wanner et al.
Gisle Langslet et al.
Objective: It is well established that higher low-density lipoprotein (LDL)-cholesterol levels are associated with increased cardiovascular risk. We analyzed whether effects of empagliflozin on cardiovascular outcomes var...
Randomized Controlled Trial
Diabetes & vascular disease research. 2020 Nov-Dec;17(6):1479164120975256. DOI:10.1177/1479164120975256 2020
Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12) [0.03%]
高心血管风险的2型糖尿病肾病发生的危险因素：一项探索性分析（DEVOTE 12）
Aslam Amod,John B Buse,Darren K McGuire et al.
Aslam Amod et al.
Aim: To investigate risk factors associated with kidney disorders in patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk. Methods: ...
Randomized Controlled Trial
Diabetes & vascular disease research. 2020 Nov-Dec;17(6):1479164120970933. DOI:10.1177/1479164120970933 2020
Epigallocatechin-3-gallate ameliorates glucolipid metabolism and oxidative stress in type 2 diabetic rats [0.03%]
表没食子儿茶素没食子酸酯通过改善氧化应激及糖脂代谢紊乱治疗2型糖尿病大鼠
Wenru Li,Chaonan Zhu,Tianheng Liu et al.
Wenru Li et al.
Aims: The objective of this study was to explore the effects of epigallocatechin-3-gallate (EGCG) on type 2 diabetes mellitus (T2DM). Main methods: ...
Baicalin ameliorates atherosclerosis by inhibiting NLRP3 inflammasome in apolipoprotein E-deficient mice [0.03%]
刺五加净素通过抑制NLRP3炎性小体改善载脂蛋白E基因敲除小鼠的动脉粥样硬化病理变化
Jingfei Zhao,Zhengtang Wang,Zhilu Yuan et al.
Jingfei Zhao et al.
Background: NLR family pyrin domain containing 3 (NLRP3) inflammasome has been implicated in the development of atherosclerosis and several studies have suggested that inhibiting NLRP3 inflammasome could be a potential th...
Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry [0.03%]
瑞典SWEDEHEART注册研究中糖尿病、二甲双胍和心梗后降糖治疗的洞见
Viveca Ritsinger,Bo Lagerqvist,Pia Lundman et al.
Viveca Ritsinger et al.
Objective: To explore real-life use of glucose lowering drugs and prognosis after acute myocardial infarction (AMI) with a special focus on metformin. Met...
SENP3 regulates high glucose-induced endothelial dysfunction via ROS dependent signaling [0.03%]
SENP3通过依赖ROS的信号转导调节高糖诱导的内皮功能障碍
Fuheng Chen,Dongdong Ma,Aizhong Li
Fuheng Chen
Background: The current study aimed to explore the role of SENP3 in endothelial cell dysfunction in a high-glucose setting. Methods: Th...
Low levels of circulating anti-ageing hormone Klotho predict the onset and progression of diabetic retinopathy [0.03%]
循环抗衰老激素克罗托水平偏低预示糖尿病视网膜病变的发生和进展
Antonella Corcillo,Nikolaos Fountoulakis,Angela Sohal et al.
Antonella Corcillo et al.
Background: Klotho is a circulating anti-ageing hormone that predicts progression of cardiovascular and renal disease. The role of Klotho in diabetic retinopathy is unknown. ...
Cardiovascular safety of Glimepiride: An indirect comparison from CAROLINA and CARMELINA [0.03%]
格列美脲心血管安全性：CAROLINA研究和CARMELINA研究的间接比较分析
Sujoy Ghosh,Pradip Mukhopadhyay,Prabhakar Pandey et al.
Sujoy Ghosh et al.
Background: Despite having unquestionable glucose lowering efficacy, current guidelines no more favour the uses of sulphonylureas for CV safety concern, except when cost is an issue. However, formal cardiovascular outcome...